HOTH | Hoth Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0600 - 1.1000
52 Week Range	0.5800 - 3.80
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	197,555
Average Volume	9,029,220
Shares Outstanding	13,147,700
Market Cap	14,199,516
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-02-15

Valuation
Profitability
Growth
Health
P/E Ratio	-0.85
Forward P/E Ratio	N/A
EPS	-1.27
1YR Price Target	9.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2
Country	USA
Website	HOTH

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

HOTH's peers: ADIL, APVO, ATXI, REVB, NRBO, VRAX, ZURA, PHIO, SONN, ATNF, CDIO, BXRX, TCON, ADTX, QNRX, ALLR, KRBP, BDRX, BWV, HILS, KPRX, ITRM, PSTV, SPRC

*Chart delayed

Analyzing fundamentals for HOTH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see HOTH Fundamentals page.

Watching at HOTH technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HOTH Technicals page.